RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events As already posted, ONCY has identified the importance of TILs as a biomarker, which is underscored by the developing ability to predict treatment response to ICI therapy (predictive/prognostic biomarkers) based on their density and location, which ONCY has demonstrated in their clinical trials. The value of a change in TILs within the TME as a response to cancer immunotherapy has also been demonstrated with immune checkpoint inhibition where an increase in TILs after treatment is prognostic, correlating with an improved survival outcome. ONCY measured the value change of TILs through the use of immunoscores like those used in ONCY's Aware-1 clinical study.